CDNA logo

CAREDX INC

CDNANASDAQ
πŸ† #1486 by market capEarnings Oct 29 Β· PostUS Equity
$71.48β–Ό $0.69 (βˆ’0.95%)
After hours Β· at close
πŸ””
Track CDNA
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.9%
7dβ–² 3.4%
14dβ–² 7.2%
30dβ–² 11.5%
ytdβ–² 279.3%
1yβ–² 401.6%
🏦Market Cap
$3.70B
Small Cap
πŸ“ˆRevenue Growth (YoY)
13.8%
Healthy
πŸ“ŠGross Margin
70.6%
High
πŸ’΅FCF Margin
18.6%
Healthy
βš–οΈP/S Ratio
8.0x
Fair
Otter Score
84
Strong

Trading Snapshot

Day Range
$70.08 – $73.03
52-Week Range
$14.23 – $72.71
Volume (shares)
110,677
Avg Volume (shares)
β€”
Shares Outstanding
51.7M
Next Earnings
2026-10-29

Fundamentals Snapshot

Annual Revenue
$380M
Last Q Revenue
$132M
P/E Ratio
32.8
P/S Ratio
8.0x
EPS (TTM)
$2.16
Dividend Yield
0.00%
Dilution (1yr)
βˆ’12.2%
CDNA logo

CAREDX INC

CDNA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$380Mβ–² +13.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
67.6%β–² +0.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$25Mβ–Ό βˆ’161.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$36Mβ–² +14.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
51.1Mβ–Ό βˆ’12.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$39Mβ–Ό βˆ’$47M YoY
StockOtter Β· stockotter.space

About CAREDX INC

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
84/100

Analyst Ratings

β“˜
Consensus
Buy
13 analysts
Strong Buy5
Buy5
Hold3
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.